Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors.
Sebastian MönchMaurice M HeimerMichael WinkelmannAnne GuertlerMax SchlaakAmanda TufmanNajib Ben KhaledEnrico de ToniChristoph B WestphalenMichael von Bergwelt-BaildonJulien DinkelPhilipp M KazmierczakMichael IngrischNabeel MansourMarcus UnterrainerLucie HeinzerlingJens RickeWolfgang Gerhard KunzPublished in: Cancer imaging : the official publication of the International Cancer Imaging Society (2023)
PsPD occurred most frequently at FU1 after initiation of ICI treatment. The two most prevalent reasons for PsPD were TL und NTL progression, with an increase in TL diameter commonly below + 100%. In few cases, PsPD was observed even if tumor markers were rising compared to baseline. Our findings also suggest a correlation between PsPD and irAE. These findings may guide decision-making of ICI continuation in suspected PsPD.